Nifedipine Capsules
Action and use
Calcium channel blocker.
Definition
Nifedipine Capsules contain Nifedipine.
Content of nifedipine, C17H18N2O6
95.0 to 105.0% of the stated amount.
Identification
Tests
Dissolution
Comply with the requirements for Monographs of the British Pharmacopoeia in the dissolution test for tablets and capsules, Appendix XII B1, using Apparatus 2. Use as the medium 900 mL of 0.1m hydrochloric acid and rotate the paddle at 50 revolutions per minute. Withdraw a sample of 10 mL of the medium and measure the absorbance of a 2-cm layer of the solution, suitably diluted if necessary, at the maximum at 340 nm, Appendix II B. Measure the absorbance of a 2-cm layer of a solution prepared by diluting a 0.025% w/v solution of nifedipine BPCRS in methanol to a suitable volume with the dissolution medium and using the dissolution medium in the reference cell. Calculate the total content of nifedipine, C17H18N2O6, in the medium from the absorbances obtained and from the declared content of C17H18N2O6 in nifedipine BPCRS.
Nitro- and nitroso-phenylpyridine analogues
Carry out the method for liquid chromatography, Appendix III D, using the following solutions. For solution (1) dissolve a quantity of the contents of the capsules containing 20 mg of Nifedipine in 8 mL of methanol and dilute to 20 mL with a mixture of 9 volumes of acetonitrile, 36 volumes of methanol and 55 volumes of water. Solution (2) contains 0.0010% w/v of dimethyl-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate BPCRS (nitrophenylpyridine analogue) in a mixture of 5 volumes of acetonitrile, 33 volumes of water and 62 volumes of methanol. Solution (3) contains 0.00050% w/v of dimethyl-2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate BPCRS (nitrosophenylpyridine analogue) in a mixture of 5 volumes of acetonitrile, 33 volumes of water and 62 volumes of methanol. For solution (4) dilute 2 volumes of a solution in methanol containing 0.25% w/v of nifedipine BPCRS, 0.0025% w/v each of the nitrophenylpyridine analogue and nitrosophenylpyridine analogue and 0.0050% w/v of propyl hydroxybenzoate to 5 volumes with a mixture of 9 volumes of acetonitrile, 36 volumes of methanol and 55 volumes of water.
The chromatographic procedure may be carried out using (a) a stainless steel column (25 cm × 4.6 mm) packed with octadecylsilyl silica gel for chromatography (5 µm) (Lichrosorb RP18 is suitable), (b) a mixture of 9 volumes of acetonitrile, 36 volumes of methanol and 55 volumes of borate buffer pH 8.0 as the mobile phase with a flow rate of 2.0 mL per minute and (c) a detection wavelength of 220 nm.
The test is not valid unless the chromatogram obtained with solution (4) closely resembles the reference chromatogram supplied with nifedipine BPCRS.
In the chromatogram obtained with solution (1) the areas of any peaks corresponding to the nitrophenylpyridine analogue and the nitrosophenylpyridine analogue are not greater than the areas of the corresponding peaks in the chromatograms obtained with solution (2) (1%) and solution (3) (0.5%), respectively.
Assay
Carry out the method for liquid chromatography, Appendix III D, using the following solutions. For solution (1) take ten capsules and break them beneath the surface of 30 mL of acetonitrile. Stir to dissolve the capsule contents. Transfer the resulting solution to a 250 mL graduated flask. Wash the capsule shells with several portions of the mobile phase, transferring the washings to the flask, add sufficient of the mobile phase to produce 250 mL and mix. If necessary, further dilute a portion of the solution with the mobile phase to give a solution containing 0.02% w/v of nifedipine. For solution (2) dissolve 50 mg of nifedipine BPCRS in 30 mL of acetonitrile and dilute to 250 mL with the mobile phase.
The chromatographic procedure may be carried out using (a) a stainless steel column (10 cm × 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (5 µm) (Hypersil C18 is suitable), (b) a mixture of 40 volumes of acetonitrile and 60 volumes of a 0.03% v/v solution of orthophosphoric acid as the mobile phase with a flow rate of 1 mL per minute and (c) a detection wavelength of 235 nm.
Calculate the content of C17H18N2O6 in the capsules using the declared content of C17H18N2O6 in nifedipine BPCRS.